Core Viewpoint - Singapore's Temasek-backed surgical robotics company, Precision Medicine, has secretly applied for an IPO in Hong Kong, aiming to raise approximately $150 million to $200 million, with details still to be confirmed [1] Company Overview - Precision Medicine was founded in 2017 by two PhD graduates from MIT and Harvard, Wang Jianchen and Gao Yuanqian [1] - The company is the first in China and the second globally to offer products for multi-port, single-port, and bronchoscopic surgical robots [1] Financial Information - The company completed a crossover financing round in December 2021, achieving a valuation exceeding $1.5 billion (approximately 10.6 billion RMB) [1] Product Details - Core products include: - Multi-port laparoscopic surgical robot MP1000 - Single-port laparoscopic surgical robot SP1000 - Natural orifice surgical robot CP1000 - The MP1000 completed its clinical trial for urological surgery in December 2021 and submitted its registration application to the National Medical Products Administration (NMPA) in January 2022 [1] - The clinical trial was led by a renowned academician, demonstrating excellent efficacy and safety [1] - As of August 2023, the MP1000 has been approved for use across all departments [1]

Core Viewpoint - Singapore's Temasek-backed surgical robotics company, Precision Medicine, has secretly applied for a Hong Kong IPO, aiming to raise approximately $150 million to $200 million, with details on the IPO scale and timing still to be determined [1] Company Overview - Precision Medicine was founded in 2017 by two PhD graduates from MIT and Harvard, Wang Jianchen and Gao Yuanqian, and is the first in China and the second globally to offer multi-port, single-port, and bronchoscopic surgical robot products [1] - The company achieved a valuation exceeding $1.5 billion (approximately 10.6 billion RMB) after completing a crossover financing round in December 2021 [1] Product Information - The core products of Precision Medicine include: - Multi-port laparoscopic surgical robot MP1000 - Single-port laparoscopic surgical robot SP1000 - Natural orifice transluminal endoscopic surgery (NOTES) robot CP1000 - The MP1000 completed its registration clinical trial for urological surgery in December 2021 and submitted its registration application to the National Medical Products Administration (NMPA) in January 2022, led by a renowned academician, demonstrating excellent efficacy and safety [1] - As of August 2023, the MP1000 has been approved for use in all departments [1]